Business Insights
Diagnostic Technologies
Diseases
Point-of-Care Testing
Research & Development
Sign In
Autoimmune
Cancer
Cardiovascular
COVID-19
Health Topics
Infectious
Autoimmune: Page 3
Quest Diagnostics launches monkeypox virus testing
By
LabPulse.com staff writers
The service will be available nationwide, with the exception of New York state, where Quest anticipates it will be available later if the New York Department of Health approves the laboratory-developed test.
July 12, 2022
Exagen highlights lupus diagnosis study
By
LabPulse.com staff writers
The trial, called Complement Activation Products vs. Standard ANA Testing: Treatment Outcomes, Diagnosis, and Economic Impact in Systemic Lupus Erythematosus (CAPSTONE), utilized multiple external databases and nearly 50,000 patient tests conducted with either Avise or standard-of-care labs.
July 4, 2022
Roche, Nordic Bioscience partner on tissue disease markers
By
LabPulse.com staff writers
According to Nordic, the extracellular matrix markers it develops are essential for chronic diseases involving tissue fibrosis and inflammation, and the collaboration with Roche will facilitate better clinical decisions in drug development and patient selection for precision medicine.
June 15, 2022
DxTerity Diagnostics launches gene expression test for lupus
By
LabPulse.com staff writers
IFN-1 is a key biomarker and important indicator of lupus severity and prognosis, the firm said, adding that high IFN-1 levels are linked to increased risk of disease severity and development of lupus nephritis.
June 9, 2022
PathAI to present AI pathology studies at London liver congress
By
LabPulse.com staff writers
The presentation abstracts describe the use of a new machine learning-enabled continuous scoring system for nonalcoholic steatohepatitis (NASH), the firm said.
June 8, 2022
FDA clears Thermo Fisher autoimmune disease tests
By
LabPulse.com staff writers
The Waltham, MA-based firm said EliA RNA Pol III is the first fully automated RNA polymerase test for systemic sclerosis available in the U.S. Its EliA Rib-P test can be used to support the diagnosis of systemic lupus erythematosus, particularly in antinuclear antibody-negative patients.
June 8, 2022
Quotient, Theradiag to partner on autoimmune disease testing
By
LabPulse.com staff writers
Under the terms of their agreement, Theradiag will supply autoimmune reagents and multiconstituent quality controls for the development of autoimmune microarrays that will be used on the Quotient MosaiQ platform.
June 7, 2022
CoVac-1 vaccine shows promise for immunocompromised patients
Walz's team used their expertise with cancer therapeutics to develop a vaccine that induces T cells in immunocompromised patients who do not produce an adequate immune response to other vaccines.
May 1, 2022
Quanterix secures breakthrough device designation for MS test
By
LabPulse.com staff writers
Simoa measures NfL in human serum and plasma and is intended to help identify patients with relapsing-remitting MS who are at risk of relapse within four years. The designation comes after a study published March 1 in The Lancet Neurology described the effective use of Simoa to interpret elevated NfL values in MS patients, the company said.
April 24, 2022
Co-Diagnostics joint venture approved for HCV test in India
By
LabPulse.com staff writers
Co-Diagnostics said its joint venture in India, CoSara Diagnostics, has received clearance to manufacture and sell its Saraq Hepatitis C (HCV) Viral Load Kit as an in vitro diagnostic.
April 18, 2022
Lifespin establishes division in the U.S.
By
LabPulse.com staff writers
Lifespin is a deep learning company that is building a diagnostic testing platform based on metabolomics. The company's U.S. subsidiary is incorporated in Delaware and initially based in Boston. Dr. Ali Tinazli, the president and CEO of Lifespin, and Dr. Trevor Hawkins, a Lifespin board member, will lead the operations in the U.S.
April 13, 2022
Siemens' MS assay receives FDA breakthrough designation
By
LabPulse.com staff writers
The assay quantitatively measures neurofilament light (NfL), a biomarker for nerve cell injury, in cerebrospinal fluid and blood. It is intended to be used in conjunction with clinical, imaging, and laboratory findings. The assay is designed to help identify adult patients with relapsing MS who are considered lower risk of disease activity.
March 24, 2022
Previous Page
Page 3 of 9
Next Page